GU Cancers 2023 | Potential new biomarkers for advanced ccRCC treatment response identified

Michael Atkins, MD, Lombardi Comprehensive Cancer Center, Washington DC, discusses new biomarkers for advanced clear cell renal cell carcinoma (ccRCC). PDL1 expression by the tumor is deemed a useful biomarker for a positive treatment response despite overall expression being low. Dr Atkins theorises this is a part of a multi component biomarker that requires more study. Poor outcome biomarkers are also highlighted utilising signatures from the CheckMate 025 trial (NCT01668784). It is suggested that further trials should be run to validate these results. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.